Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
0.8567
-0.0444 (-4.93%)
At close: Oct 2, 2026, 4:00 PM EDT
0.8907
+0.0340 (3.97%)
After-hours: Oct 2, 2026, 7:59 PM EDT
Compass Therapeutics Employees
Compass Therapeutics had 39 employees as of December 31, 2025. The number of employees increased by 4 or 11.43% compared to the previous year.
Employees
39
Change (1Y)
4
Growth (1Y)
11.43%
Revenue / Employee
n/a
Profits / Employee
-$1,883,231
Market Cap
154.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 39 | 4 | 11.43% |
| Dec 31, 2024 | 35 | 3 | 9.38% |
| Dec 31, 2023 | 32 | 6 | 23.08% |
| Dec 31, 2022 | 26 | 2 | 8.33% |
| Dec 31, 2021 | 24 | -7 | -22.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Molecular Partners AG | 134 |
| Acumen Pharmaceuticals | 61 |
| PepGen | 57 |
| Protara Therapeutics | 46 |
| NovaBridge Biosciences | 30 |
CMPX News
- 10 days ago - Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum - TheFly
- 10 days ago - Wedbush downgrades Compass Therapeutics as FDA throws wrench at tovecimig - TheFly
- 10 days ago - Compass Therapeutics price target lowered to $4 from $8 at Guggenheim - TheFly
- 10 days ago - Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright - TheFly
- 10 days ago - Compass Therapeutics price target lowered to $4 from $10 at Citizens - TheFly
- 11 days ago - Compass Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 11 days ago - Compass Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 11 days ago - Compass Therapeutics says FDA requests new trial for tovecimig - TheFly